About ACD Bio
ACD Bio is a Healthcare company based in Newark (United States) founded in 2006, and was acquired by Bio-Techne in July 2016. Developer of a transnational research platform for biomarker analysis. ACD Bio has raised $39.4 million across 8 funding rounds from investors including New Leaf Venture Partners, Bio-Techne and HHS. Its website acdbio.com draws about 21 thousand monthly visits. ACD Bio offers products and services including RNAscope Assay, BaseScope Assay, and miRNAscope Assay. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is Advanced Cell Diagnostics, Inc. Its competitors include GenScript, Teknova and Meridian Bioscience; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2006 and based in Newark, United States, operations focus on biotechnology for biomarker analysis. A proprietary RNAscope technology is utilized to detect and quantify RNA biomarkers at single-molecule sensitivity in situ. Clinical-grade assay development and biomarker validation services are offered, along with companion diagnostic support. Targeted therapies for cancer and other diseases are facilitated through the platform, which encompasses RNAscope probes, reagent kits, hybridization systems, and software.
- Headquarters Newark, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website acdbio.com
- Social LinkedIn X Facebook
- Acquired by Bio-Techne (Jul 2016)
- Legal Name Advanced Cell Diagnostics, Inc.
- Annual Revenue$576.82 K (USD)-41as on Dec 31, 2020
- Net Profit-$264.49 K (USD)-3889as on Dec 31, 2022
- Total Equity Funding$39.4M (USD)
in 8 rounds
- Latest Funding Round$22M (USD), Series C
Jun 2015
- InvestorsNew Leaf Venture Partners
& 7 more
- Acquired byBio-Techne
(Jul 2016)
Products & Services of ACD Bio
ACD Bio offers a comprehensive portfolio of products and services, including RNAscope Assay, BaseScope Assay, and miRNAscope Assay.
Enables visualization of single RNA molecules in tissues.
Detects RNA targets with high sensitivity in research samples.
Facilitates microRNA detection for gene regulation studies.
Funding Insights of ACD Bio
ACD Bio has successfully raised a total of $39.4M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.4M
- Total Rounds 8
- Last Round Series C — $22M
- First Round $4.07M
(Sep 2006)
- Investors Count 7
All 8 funding rounds of ACD Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $22M | Series C | – | Summit Partners | |
| Oct 2014 | $1.4M | Grant | – | – | |
| Nov 2012 | $12M | Series B | – | – | |
| Sep 2012 | $970,470 | Grant | – | – | |
| Oct 2010 | $3M | Grant | – | – | |
| Sep 2009 | $5.4M | Series A | – | – | |
| Jul 2008 | $4.07M | Grant | – | – | |
| Sep 2006 | $4.07M | Grant | – | – |
8 investors in total: 8 institutional.
Investors in ACD Bio
ACD Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Bio-Techne and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
| kensonventures.com | ||||
Summit Partners is recognized as a growth equity investment firm. | summitpartners.com | Boston, United States | ||
A venture capital firm focused on technology and innovation investments. | 5ycap.com | Shanghai, China | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States |
Investor details for ACD Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ACD Bio
4 dated milestones of ACD Bio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded ACD Bio is founded.
- Funding First funding round of $4.1M.
- Funding Latest funding round, Series C, of $22.0M.
- Exit Acquired by Bio-Techne.
Competitors of ACD Bio
ACD Bio has 3 listed competitors in our database, 1 of them funded. They include GenScript, Teknova and Meridian Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| teknova.com | 1996 | Hollister, United States | 290 | Molecular biology reagents and kits are supplied for research applications. | ||
| meridianbioscience.com | 1976 | Ohio, United States | Molecular diagnostic device and kits |
Detailed competitors of ACD Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ACD Bio
The website of ACD Bio (acdbio.com) receives about 21.2K visits a month.
- Monthly visits21.2K
▼ 20.6% vs previous month
Websites whose visitors overlap most with ACD Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| irvinesci.com | 100% | 6.6K | #3,329,806 | View details | |
euchromatin.net | euchromatin.net | 95% | – | ||
spacedu.com | spacedu.com | 93% | – | ||
rnasociety.org | rnasociety.org | 93% | #1,221,925 | – | |
| bio-techne.com | 93% | 218.1K | #187,423 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for ACD Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ACD Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acd Bio
Complete news archive for ACD Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACD Bio
ACD Bio was founded in 2006.
ACD Bio is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
ACD Bio is a funded company, having raised a total of $39.4M across 8 funding rounds to date. The company's 1st funding round was a Grant of $4.07M, raised on Sep 2006.
Annual revenue of ACD Bio is $576.82K as on Dec 31, 2020.
Founded in 2006 and based in Newark, United States, operations focus on biotechnology for biomarker analysis. A proprietary RNAscope technology is utilized to detect and quantify RNA biomarkers at single-molecule sensitivity in situ. Clinical-grade assay development and biomarker validation services are offered, along with companion diagnostic support. Targeted therapies for cancer and other diseases are facilitated through the platform, which encompasses RNAscope probes, reagent kits, hybridization systems, and software.
ACD Bio's top competitors include Meridian Bioscience, GenScript and Teknova.
ACD Bio offers RNAscope Assay, BaseScope Assay, and miRNAscope Assay.
ACD Bio has 8 investors. Key investors include New Leaf Venture Partners, Bio-Techne, HHS, National Cancer Institute, and Kenson Ventures.
ACD Bio operates through Advanced Cell Diagnostics, Inc..
Yes. ACD Bio was acquired by Bio-Techne in July 2016.